THY1 and neoplasm: In PanNENs, CSCsmarked by aldehyde dehydrogenases or CD90 have been identified, and targetingCSCs with inhibitors of molecular pathways has shown therapeutic potential.Overall, while evidence exists for the presence of CSCs in NENs, either the CSCfield has neglected NENs or the NEN field has not fully embraced the CSC model.Both might apply and/or may be a consequence of the fact that NENs are arelatively rare and heterogeneous tumor entity, with confusing histology andnomenclature to match.